Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danuglipron DDI with Itraconazole and Cyclosporine
NCT06541678Phase 1Completed
- Sponsor
- Pfizer
- Start
- Dec 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of danuglipron in type 2 diabetes mellitus (T2DM) and obesity, sponsored by Pfizer. Primary endpoints: Area Under the Concentration-Time Curve From Zero to Infinity and Maximum Plasma Concentration. Started Dec 2024; status: completed.
02
Drugs
danuglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06541678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06541678.